concentration in comparison to placebo-treated mares. This reduction in eCG concentration was most pronounced at 7 days following treatment, with a diminished response noted throughout the remainder of thestudy. Return tocyclicity couldnot beassessed under the confinesofthisstudyasmareswere treated in late fall of Central Kentucky and therefore became acyclic due to winter anestrus. Future research is war- ranted to determine the clinical ramifications of this decrease in eCG concentrations following treatment with the immunomodulatorMCWF.
Acknowledgments
Declaration of Ethics The Authors have adhered to the Principles of VeterinaryMedical Ethics of the AVMA.
Conflict of Interest
This study was funded in part from unrestricted gifts by NovaVive in support of Dr. Troedsson’s research program, and Settle® was provided by the company free of charge for this project.
Footnote aSettle®, NovaVive USA Inc., Athens, GA 30601.